{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125920","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.583975+00:00","generated_at":"2026-05-30T01:00:59.988469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer","bullets":["Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.","Cash and securities $202.8M as of Sep 30, 2024; expected to fund into H2 2026.","ACR-368 Phase 2b endometrial cancer: confirmed ORR 62.5% in OncoSignature-positive patients (p=0.009).","ACR-2316 Phase 1 dose-escalation cohort fully enrolled; initial data expected H2 2025.","Company sees endometrial cancer as first potential approval opportunity for ACR-368."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125920","json":"https://secwatch.observer/filing/0000950170-24-125920.json","markdown":"https://secwatch.observer/filing/0000950170-24-125920.md","text":"https://secwatch.observer/filing/0000950170-24-125920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/0000950170-24-125920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/acrv-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:00:59.988469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}